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Giant unilamellar vesiclesPrP106–126 conserves thepathogenic andphysicochemical properties of the Scrapie isoformof theprion protein.
PrP 106–126 and other amyloidal proteins are capable of inducing ion permeability through cell membranes, and
this property may represent the common primary mechanism of pathogenesis in the amyloid-related degenera-
tive diseases. However, for many amyloidal proteins, despite numerous phenomenological observations of their
interactionswithmembranes, it has been difﬁcult to determine themolecularmechanisms bywhich the proteins
cause ion permeability. One approach that has not been undertaken is the kinetic study of protein–membrane in-
teractions. We found that the reaction time constant of the interaction between PrP 106–126 and membranes is
suitable for such studies. The kinetic experimentwith giant lipid vesicles showed that themembrane area ﬁrst in-
creased by peptide binding but then decreased. The membrane area decrease was coincidental with appearance
of extramembranous aggregates including lipidmolecules. Sometimes, themembrane areawould increase again
followedby another decrease. The kinetic experimentwith small vesicleswasmonitored by circular dichroism for
peptide conformation changes. The results are consistent with a molecular simulation following a simple set of
well-deﬁned rules. We deduced that at the molecular level the formation of peptide amyloids incorporated
lipidmolecules as part of the aggregates. Most importantly the amyloid aggregates desorbed from the lipid bilay-
er, consistent with themacroscopic phenomena observedwith giant vesicles. Thus we conclude that themain ef-
fect of membrane-mediated amyloid formation is extraction of lipid molecules from the membrane. We discuss
the likelihood of this effect on membrane ion permeability.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Amyloids and their toxicity have been related to the onset and pro-
gression of amyloidoses, including neurodegenerative diseases and type
II diabetes [1,2]. In each case,misfolding and aggregation of a native pro-
tein are correlated to cell death. Studies from many laboratories have
suggested that the molecular agents causing amyloidoses are not the
macroscopic, insoluble protein ﬁbrils that have long been taken as the
deﬁning feature of these disorders; instead the soluble, transient,
preﬁbrillar protein oligomers have been implicated as the primary caus-
ative agents [3–8]. While the molecular structures of the ﬁbrillar amy-
loids [9–11] and the preﬁbrillar oligomers [8,12] are being clariﬁed,
the mechanism by which either the ﬁbrillar or the preﬁbrillar species
trigger cell death is still unknown. Since the early 2000's there emerged
several lines of evidence pointing to a common mechanism for most or
all amyloid proteins. Firstly, the cytotoxicity of a range of proteins that
are able to aggregate in vitro into ﬁbrils but are not associatedwith am-
yloid diseases suggests inherent toxicity of protein aggregates [1,13].
Secondly, all amyloid ﬁbrils have a common atomic structure [10,11,14] and so do the preﬁbrillar protein oligomers [2,7,12]. Thirdly, many
amyloid proteins have been found to induce ion leakage through lipid
bilayers [15,16], thus if acting on cell membranes the effect could lead
to loss ofmembrane potential and cell death. Studies [16] found that un-
related amyloidal proteins all permeabilized lipid bilayers to a similar
degree and all ion-conductivities occurred without any evidence of dis-
creet channel or pore or ion selectivity. This is consistent with indepen-
dent reports of unregulated membrane permeabilization induced by
many known amyloid proteins, although some of them were assumed
to form pores based on pore-like AFM images (see review [2]).
There have been many studies on membrane binding by amyloid
peptides and subsequent structural transformations of the peptides
(see reviews [2,17,18]). In general, at very low concentrations, for ex-
ample in biological ﬂuids, the peptides remainmonomeric and unstruc-
tured. However, amyloid peptides being amphipathic have relatively
high afﬁnities for membrane binding. Upon binding to lipid bilayers,
the peptides transform to helical and/or β-sheet structures, depending
on the peptide to lipid ratios. There are at least two different hypotheses
about how amyloid peptides might affect the membrane permeability
to ions. One hypothesis is that the membrane-bound amyloids include
pore-like protoﬁbrils [19–23] that allow ions to pass through (see
review [2]). Another hypothesis is that amyloids cause membrane
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formation [24–30]. However, most experiments were not able to show
how amyloid peptides perturbed membrane structures.
Because this is such a difﬁcult problem, we believe that it is useful to
know the time sequence of peptide–membrane interactions as a func-
tion of peptide to lipid ratio. This will help clarify the molecular process
of the interactions. Such kinetic studies are possible only if the time con-
stant of interaction is compatible with themethod of measurement.We
found such a case in PrP 106–126.
Many notable neurodegenerative diseases in mammals such as
Creutzfeldt–Jakob disease, Kuru and bovine spongiform encephalopa-
thy are associated with an abnormal Scrapie isoform of prion protein
(PrPSc) [31]. PrP 106–126, a 21-residue peptide derived from the un-
structured N-terminal of the full-length prion protein, has been found
to form amyloid ﬁbrils [7,32,33] and conserve the pathogenic and phys-
icochemical properties of PrPSc [34–36], consequently it has been used
as amodel peptide to study prion-related diseases. Likemany other am-
yloid peptides, PrP 106–126 has been shown to interact with model
membranes of various compositions [37], induce liposome aggregation
[37,38], and form ion channels or pores in planner lipid bilayers [39,40].
On the other hand, it was also found to increase themembrane conduc-
tancewithout any evidence of discrete channel or pore formation or ion
selectivity [16]. Miura et al. [41] studied the circular dichroism (CD)
spectra of PrP 106–126 as a function of peptide-to-lipid ratio and the
role of negatively charged lipids, particularly that of gangliosides in its
β-sheet formation. Their results are invaluable for our design of kinetic
experiments.
2. Experiment and method
2.1. Materials
1,2-Dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dioleoyl-sn-
glycero-3-phospho-(1′-rac-glycerol) (DOPG), and 1,2-dioleoyl-sn-
glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl)
(Rh-DOPE) were purchased from Avanti Polar Lipids (Alabaster, AL). PrPFig. 1. Four representative runs of an aspiratedGUV (containing 1%Rh-DOPE) exposed to 10 μM
GUV,ΔA/A, was calculated from the change of the protrusion length as shown in theﬂuorescenc
squares. Scale bar= 10 μm. Note that extramembranous aggregates containing dye lipid began
resentative runs showing that themembrane area increased and decreased twice in 10min, and
once in 10 min.106–126 with blocked termini (acetyl-KTNMKHMAGAAAAGAVVGGLG-
amide) was synthesized by GenScript (Piscataway, NJ) and PrP 106–126
with free termini (KTNMKHMAGAAAAGAVVGGLG) was purchased
from AnaSpec (Fremont, CA), both are of N95% purity. Dipotassium hy-
drogen phosphate (K2HPO4) and potassium dihydrogen phosphate
(KH2PO4) were from Fisher Scientiﬁc (WalthamMA). All materials were
used as delivered.
2.2. Kinetic experiment with SUV
To form small unilamellar vesicles (SUVs) of 7:3 DOPC and DOPG,
lipids were ﬁrst dissolved in chloroform to a concentration of 25 mg/ml.
The solvent ﬁrst evaporated under a stream of nitrogen and was further
removed in a vacuum desiccator for at least 60 min. Multilamellar vesi-
cles (MLVs) were prepared by swelling the resulted lipid ﬁlm in aqueous
solution to a ﬁnal concentration of 10mg/ml, then vortexing periodically
for 5 min. A cup-horn sonicator was then used to sonicate the MLVs for
20 min to produces small unilamellar vesicles (SUVs). Finally, SUVs
were passed through track-etched polycarbonate membranes with 30-
nm pores at least 19 times using a mini-extruder apparatus (Avanti
Polar Lipids, Alabaster, AL, USA). All SUVs were used on the same day of
preparation.
PrP peptides at a ﬁnal concentration of 100 μM were mixed with a
SUV suspension in phosphate buffer (pH 6.0) at a chosen peptide-to-
lipid ratio for CD measurement. CD spectra were measured in a Jasco
(Tokyo, Japan) J-810 Spectropolarimeter. The spectra were scanned at
room temperature in a sealed, quartz optical cell with a 1 mm path
length, from wavelength 185 to 250 nm at a scan rate of ~4 min/scan.
The ﬁrst scan was measured right after the mixing and subsequently
the sample was scanned at the time indicated in the ﬁgures below.
2.3. Kinetic experiment with aspirated GUV
The method of micropipette aspiration of giant unilamellar vesicles
(GUVs) was a modiﬁcation of the original method of Kwok and Evans
[42] as described in Sun et al. [43,44]. A micropipette was connected toPrP 106–126 (out of 26 individual runs). The fractional change of themembrane area of the
e images at the top, taken at 0, 15, 95, 318, 598 s from left to right for the run labeled by red
to appear as the protrusion length decreased for the ﬁrst time. The plot includes two rep-
two other representative runs showing that themembrane area increased and decreased
Fig. 2. (A) CD spectra of PrP 106–126 in three different conﬁgurations: α-helix (blue), β-
sheet (red), and random coil (green) in a unit expressed inmdeg for the same concentra-
tion of 100 μMof peptide. (B) Time series of CD spectra, frombottom to top, for 100 μMPrP
peptide in 0.7mg/ml lipid vesicles (Pt/L=1/9). (C) Time series of CD spectra, from bottom
to top, for 100 μM PrP peptide in 4 mg/ml lipid vesicles (Pt/L=1/50). In both (B) and (C),
the data are shownby the symbols indicated by the time ofmeasurement, and the red dots
are the ﬁt to a linear combination of three spectra shown in (A). All measurements were
made with the same amount of peptide, so all CD spectra are normalized relatively to
each other.
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ducing amembrane tension ~ 0.4mN/m) in thepipettewas produced by
adjusting the height of thewater level reference to the atmosphere pres-
sure [43]. An aspirated GUV consisted of a spherical part and a cylindri-
cal part (a protrusion into the micropipette), where Lp the length of the
protrusion, Rp the radius of the micropipette, and Rv the radius of the
spherical part were carefully measured. Then it was straightforward to
show ΔA= 2πRpΔLp + 8πRvΔRv, and ΔV= πRp2ΔLp + 4πRv2ΔRv [42]. As
long as the osmolality balance between the inside and outside of the
GUV was maintained, there should be no change of the GUV volume
(the effect of the pressure change by suctionwas so small that its contri-
bution to the chemical potential change was ~10−3 that of osmolality).
Under the condition ΔV=0, ΔAwas directly proportional to ΔLp: ΔA=
2πRp(1 − Rp/Rv)ΔLp. The fractional area change ΔA/A was calculated
from the change of theprotrusion lengthΔLp. The osmolality of every so-
lution used in the GUV experiment was measured by a dew-point
Wescor osmometer (model 5520) (Logan, UT).
There is an important limitation to the aspirated GUV experiment
due to water evaporation.Water evaporationwould increase the osmo-
lality of the sample solution relative to that inside the GUV and conse-
quently cause an increase in the protrusion length, creating errors,
i.e., a background increase, in the measurement of membrane area
change [43]. By humidifying the air surrounding the sample chamber,
we could limit the errors of the ΔA/A measurement to a negligible
level within the ﬁrst several minutes, and then the background would
more or less increase linearly to less than 1% within 10 min of GUV ex-
periment [43]. Thus we limited our aspirated GUV experiments towith-
in 10 min, and understood that the measured values of ΔA/A might
include positive errors up to 1% at the end of 10 min.
3. Results
3.1. PrP peptides
We experimented with PrP 106–126 both with free termini and
blocked termini. Both exhibited the same CD spectra and have the
same structure transformation kinetics.We found that theGUV response
to the free-termini PrP was relatively fast, therefore it was used for the
GUV experiment to shorten the time of observation. The blocked PrP
peptide has a slower structural transition in SUV experiments. It is
more suitable for the SUV kinetic experiments. As shown by Miura
et al. [41], the membrane binding afﬁnity of PrP peptides is enhanced
by lowering pH to ~6. We performed all of our experiments at pH = 6.
We stress that this is only to speed up the kinetics. The results of PrP–
lipid interactions are not pH-dependent as far as we know.
3.2. Macroscopic observation with GUV
GUVs of 7:3 DOPC/PGwere produced in 200mMsucrose solution [43,
45]. For each run of experiment, an aspirated GUV was transferred to a
chamber containing PrP peptides in a phosphate buffered (2 mM,
pH 6.0) sucrose (~198 mM) solution of osmolality equal to that of the
GUV content. Without PrP peptides in the solution, the GUVs showed
no changes. With 50 μM blocked termini PrP peptides, we found that
the GUVmembrane area increased b 2% in 10 min. Free termini PrP pep-
tides have a strongermembrane binding afﬁnity than blocked termini PrP
peptides. With free termini PrP peptides, we observed a membrane area
increase ≲ 2% in 10min for peptide concentrations ≤ 5 μM.We performed
the GUV experiments with free termini PrP peptide at 10 μM.
Fig. 1 shows representative GUV responses to 10 μM free termini PrP
peptide. In general, themembrane area of the GUV initially increased 3–
4% within 3 min. Then the protrusion length began to decrease and
extramembranous aggregates appeared. The aggregates were most
clearly seen when they appeared near the equator of the GUV where
the microscope's focal plane was set. In about 30% of the runs, the
GUV membrane area increased and decreased twice within 10 min.This phenomenon has been previously observed in GUVs interacting
with penetratin [45].
3.3. Kinetic experiment with SUV
PrP peptide was mixed with SUV (7:3 DOPC/DOPG) suspensions at
different lipid concentrations from 0.35 mg/ml to 8 mg/ml. The back-
ground CD spectrum for each sample was measured without the pep-
tide. This background was removed from each reported CD spectrum
below. All samples had the same amount of peptide (100 μM) except
for lipid at 8 mg/ml which was mixed with 50 μM PrP. First we
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(Fig. 2A). In a pure phosphate buffer, the peptide was in a random coil
conﬁguration; in 4 mg/ml SUV of 1:1 DOPC/DOPG suspension the pep-
tide had a CD of the α-helical conﬁguration, closely similar to its CD in
tetraﬂuoroethylene; in 2 mg/ml suspension the peptide evolved to a
stable β-sheet conﬁguration after one day (Fig. 2A).
Each kinetic experiment startedwith PrP peptides in themonomeric
random-coil state. Lipid vesicles of DOPC/DOPG 7:3 at various total pep-
tide to lipid ratios (Pt/L) weremixedwith the peptide. The ﬁrst CDmea-
surement of a sample completed in about 4 min (shown as t = 0 in
Figs. 3 and 4). Subsequently, depending on the rate of change, CD was
measured at longer time intervals. As examples, two series of kinetic
measurements are shown in Fig. 2B and C. Each CD spectrum was
decomposed into the components of random-coil, α-helical and β-
sheet states by linear ﬁtting. The kinetic data are presented in Fig. 3 for
large Pt/L values and in Fig. 4 for small Pt/L values. The SUVs in the sam-
ples reported in Figs. 3 and 4 did not cause signiﬁcant light scattering.
However samples of any lower Pt/L value (higher lipid concentrations)
would have signiﬁcant light scattering that distorts the CD spectra.Fig. 3. Kinetics of PrP peptide conformation changes at high total peptide to lipid ratios (Pt/L). Th
(Pt/L=1/9), and in 1.5mg/ml lipid (Pt/L=1/19). Data are on the left column (note the initial ti
ber of lipid vesicles in simulations (see text or the Supporting information). Each simulation resu
in random coils, blue α-helices and red β-sheets. The black dashed lines in simulations are the4. Discussion
Amyloid aggregation of proteins in solution has been described as
nucleation-dependent polymerization [1,46]. It has been argued that
this is a general property of polypeptides [13,47], but at physiological
concentrations polymerization is normally prevented from occurring
by the energy barrier for nucleation [1]. Here we take the view that
the toxicity of the amyloid peptide occurs if the amyloid formation
process is mediated by cell membranes, since membrane perme-
abilization to ions has been repeatedly detected in the presence of
amyloidal peptides (see refs cited in [2,16]). Indeed, membranes have
been implicated as the catalyst that facilities amyloid formation (see
review [17,48,49]). For many peptides, such as Aβ [17,50], IAPP [18,29,
51], PrP [41], and penetratin [45,52] it has been known that unstruc-
tured peptide monomers in solution transform into α-helices upon
binding to membranes. As the bound peptide to lipid ratio, Pb/L, in-
creases, peptides were found in β-sheets, presumably in an aggregated
form. Is there an energy barrier for the membrane-mediated β-sheet
formation? What is the effect of this transformation to the membranee sample conditions were: 100 μMPrP in 0.35mg/ml lipid (Pt/L=1/4), in 0.7 mg/ml lipid
me scale expansion), and the corresponding simulations on the right, wherem is the num-
ltwas the averageofﬁve repeated simulations. Green represents the fraction of the peptide
“starting time” to be compared with the ﬁrst measurements in the kinetic experiments.
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membranes is indeed the cause of toxicity.
We suspect that amyloid formation might affect the membrane
properties because we have observed in GUV experiments that amyloid
peptides, such as hIAPP [29] and penetratin [45,52], formed
extramembranous aggregates including lipids that desorbed from the
lipid bilayers of the vesicles. The appearance of the extramembranous
aggregates was coincidental with the decrease of membrane area, con-
sistent with the membrane losing lipid molecules [29,45,52]. These
weremacroscopic observations. The aggregates caused by amyloid pep-
tidesmust grow to amicron or larger scale to be seen undermicroscope.
The time constant for forming macroscopic aggregates varies with pep-
tides: relatively short for penetratin [45,52], longer for hIAPP [29]. If lipid
vesicles were suspended in solution with amyloid peptides, eventually
very large aggregates including lipids would appear [29,53]. The effect
of the PrP peptide on GUVs (Fig. 1) is the same as penetratin and
hIAPP. First the binding of PrP peptide to a GUV caused a membrane
area expansion implying that the peptides inserted into the headgroup
region of the bilayer (this was called a wedge effect [54,55]). Then theFig. 4. Kinetics of PrP peptide conformation changes at low total peptide to lipid ratios (Pt/L). Th
(Pt/L=1/50); 50 μMPrP in 8mg/ml lipid (Pt/L=1/200). Data are on the left column (note the in
wherem is the number of lipid vesicles in simulations (see text or the Supporting information)
fraction of the peptide in random coils, blue α-helices and red β-sheets. The black dashed lines
kinetic experiments.expansion stopped and the area began to decrease indicating that the
lipid bilayerwas losing peptide or lipid or both.Within the experimental
time limit of ~10 min (see Experiment and method), sometimes the
GUV membrane area would increase and decrease twice. Large
extramembranous aggregates including lipid molecules were occasion-
ally visible during the membrane area decrease. If lipid vesicles were
suspended in a solution containing PrP 106–126, networks of aggre-
gates, characteristic of amyloid aggregation including lipids [29,53], in-
evitably appeared (Fig. 5). [Note that the time scale for aggregation is
much shorter in a GUV experiment (Fig. 1) than in a SUV suspension
(Figs. 3, 4, 5), because the peptide to lipid ratio is many orders of magni-
tude higher in the former than in the latter [56].] The GUV experiments
offered a large scale observation of the lipid extracting effect. To see if
the same effect is extended to themolecular level, we performed kinetic
experiments with SUVs where we monitored the peptide conformation
transformation and interpreted the data with a simple molecular
simulation.
In the kinetic experiment with SUVs, the ﬁrst CD scan
completed ~ 4 min after mixing was always a linear combination ofe sample conditionswere: 100 μMPrP in 2mg/ml lipid (Pt/L=1/25), and in 4mg/ml lipid
itial time scale expansion for Pt/L=1/25), and the corresponding simulations on the right,
. Each simulation result was the average of ﬁve repeated simulations. Green represents the
in simulations are the “starting time” to be compared with the ﬁrst measurements in the
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with increasing lipid concentration. The kinetics of peptide binding
to lipid vesicles was too fast to be detected by CD measurement.
(We measured the spectral intensity change at one wavelength of
201.5 nm immediately after mixing and found that the change was
completed within 20 s—see Supporting information Fig. S1.) As
time went on, both the α-helical and random coil components de-
creased while the β-sheet component increased (Figs. 3 and 4). We
used a set of simple rules to numerically simulate these data (see de-
tails in the Supporting information). A simulation starts with 100
peptide monomers and m number of vesicles, each of which has 12
lipid-sites for peptide binding. Each Monte Carlo (MC) step picks a
peptide: (i) If the peptide is random-coil, it probabilistically binds
to an empty lipid-site and transforms to a helix, otherwise remains
a random-coil. If the peptide ﬁnds a binding site in a vesicle, and if
the number of helices in the vesicle is less than a critical Pb/L* value
of 1/4, the helices in this vesicle stay. But if the number of helices
in the vesicle reaches a Pb/L value of 1/4, all of the peptides in that
vesicle transform to a β-aggregate and simultaneously the vesicle
loses 4 lipid-sites as part of the aggregate. After the desorption of
the peptide–lipid aggregate, the vesicle becomes smaller and con-
tinues to bind peptides. (ii) If the MC step picks a helical peptide,
the helix is allowed to transfer to another empty lipid-site, presum-
ably through vesicle–vesicle collision. Again the rule of transforma-
tion to a β-aggregate applies after the transfer. (iii) If the MC step
picks a β-sheet peptide, nothing changes. The actual program is
given in the Supporting information. The simulation results are com-
pared with the kinetic data in Figs. 3 and 4.
Bymaking theMC steps corresponding to the experimental time, we
note that in the experiment all peptides react withmembranes simulta-
neously, while a simulation takes only one peptide molecule in each
step. Therefore the “time” has been stretched out in simulations. Since
the binding of peptides to vesicles was too fast to be measured by CD,
in each simulation (Figs. 3 and 4),we drew a “starting time” (the dashed
lines in Figs. 3 and 4) corresponding to the time of the ﬁrst measure-
ment. We also note that in the experiment there is a time delay inFig. 5. The ﬂuorescence images of 100 μM PrP peptide mixed with 0.5 mg/ml lipid vesicles ma
aggregates were too small to be detected, but the aggregates grew to macroscopic size as tim
the lipid was part of the aggregates formed by PrP peptides. Scale bar = 50 μm.convertingα-helices toβ-aggregates—note that theβ-sheet component
was zero at theﬁrst CDmeasurement in each casewhichwas completed
in ~4 min while the initial peptide binding was completed within 20 s.
This suggests that there might be a nucleation barrier for membrane-
bound helical peptides converting to β-sheet aggregates. Thus our
“starting time” in simulation was the time the α-helix component
reached the maximum, because in the experiment this was when β-
sheets began to form. This “starting time” took more MC steps as the
ratio Pb/L decreased, because more peptides were initially bound to
the vesicles.
Once we take into account the MC “time,”we see an excellent qual-
itative agreement between the kinetic data and the simulations follow-
ing the simple rules described above for a wide range of peptide to lipid
ratios. Thus we are able to draw the following conclusions: (1) The pep-
tides must bind to a membrane and turns into an α-helix before
converting into a β-sheet. It is very well known that the amyloid
peptides appear as helices at low Pb/L, but asβ-sheets at high Pb/L. How-
ever, only the kinetic experiments show that β-sheets come from heli-
ces, not directly from random coils. (2) The membrane bound helices
must reach a critical value of Pb/L* before converting into β-sheets. In
the Pt/L = 1/200 case, all peptides remained in the α-helical state;
there were no β-sheets, because Pb/L was below the critical value.
(3) The GUV experiments showed large PrP peptide aggregates
desorbed from the lipid bilayer, same as in previous GUV experiments
with other amyloid peptides [29,45,52,57]—we called this a lipid
extracting effect because lipid molecules were part of the
extramembranous aggregates. Accordingly in simulations we assumed
that the lipid vesicles lost lipid molecules whenever β-sheet aggregates
were formed. (4) After losing lipid molecules to extramembranous ag-
gregates, the vesicle membrane continued to bind peptides as demon-
strated in the GUV experiment (Fig. 1). We wish to draw attention to
the kinetic results, particularly obvious in Fig. 3, that the amount of
ﬁnal β-sheet component was much higher than the maximum α-
helical component from the initial binding, which completed within
~20 s. Thus a substantial amount of the ﬁnal β-sheet component had
to come from the peptides subsequently bound to lipid vesicles afterde of 7:3 DOPC/DOPG and 1% of Rh-DOPE (Pt/L= 1/9), at the time indicated. Initially the
e went on. An additional confocal image was shown for day 5. These images show that
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desorbed from the lipid vesicles. In the high Pt/L cases (e.g., Pt/L= 1/4
and Pt/L=1/9), the lipidmoleculeswere eventually used up—all became
part of the β-sheet aggregates, and the excessive peptides that had not
bound to vesicles remained in the random coil state.
Thus we conclude that the main perturbation effect the amyloid
peptides exert on membranes is extracting lipid molecules from the
membrane via the process of membrane-mediated amyloid formation.
Otherwise the process left the GUV intact. This kinetic study offers a
model of peptide–membrane interaction for the lipid extracting effect.
Can this effect cause the membrane permeable to ions?
5. Lipid extraction and ion leakage
Ion permeation through a membrane has been extensively studied
by molecular simulations [58–62]. The consensual results can be sum-
marized as follows: (i) ion permeation is an activated process; sponta-
neous ion permeation is rare [61,62]; (ii) ions enter the bilayer with a
trail of water molecules called water ﬁngers [58] (the potential energy
for an isolated ion in membrane is too high). The water ﬁnger is lined
by lipid headgroups. This results in a major rearrangement of neighbor-
ing lipids, commonly calledwater pore defects [58–62]; (iii) simulations
by displacing a pair of chain-to-chain lipidmolecules from a bilayer cre-
ate awater pore defect, allowing ion permeation [60]; and (iv) the tran-
sient water pores created by activated ion permeation or by the lipid
molecule displacement have radii less than 1 nm [59], and life time of
10–100 ns [59,60]. Thus it is reasonable to expect that lipid extraction
from a membrane can lead to ion permeability.
Currently there are several different suggestions about how amyloid
formation might cause ion permeabilization in membranes. It has been
suggested that amyloid formation includes pore-like structures within
the membrane [19–23] (see review [2]); amyloid formation creates
defects in membrane structures [26,27,30]; or the process of amyloid
formation extracts lipid molecules and damages the membrane [24,
53]. Herewe showed that the lipid extracting effect by amyloid peptides
previously observed at the macroscopic scale in GUVs is consistent at
the molecular scale by kinetic experiments with SUVs. We showed
that membrane-mediated amyloid formation is a cooperative transition
by membrane-bound α-helices to β-aggregates which occurs only
when Pb/L exceeds a critical value. The β-aggregates desorb from the
membrane, but otherwise leave the GUV intact. The desorbed aggre-
gates include lipid molecules, implying lipid extraction from the mem-
brane. Therefore we propose that the process of lipid extraction
creates transient water defects in the membrane resulting in ion
permeability.
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